• PlantX announced the acquisition of Little West, a California-based producer of ultra-premium cold-pressed juices
• Acquisition to help both companies capitalize on mutual strengths to enhance PlantX’s growth going forward
• The company appears poised to develop a brand portfolio with plans to expand into cosmetics, clothing, and its own water brand.

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant-based, has announced the closing on a previously announced acquisition of Little West LLC (https://ibn.fm/5OzYA). The company had previously announced that it entered into a membership interest purchase agreement through its wholly-owned subsidiary, PlantX Lifestyle USA Inc., to acquire all of the issued and outstanding limited liability membership interest of the acquired company. Little West is a California-based small business founded in 2013 by Cassandra Troy, Andrew Walker, Brad Neumann to produce ultra-premium cold-pressed juices. It soon became a leader in quality standards and fresh taste for cold-pressed fruit beverages. Little West delivers small-batch, cold-pressed juices with no preservatives, concentrates, or added sugars. Every juice contains 2-4 pounds of non-GMO hand-selected and cold-pressed produce that is bottled within 48 hours of harvest for peak freshness, flavor, nutritional value, and health benefits. As such, it appears to be the perfect fit for PlantX’s offering and valuable addition to its brand portfolio. Little West will continue to be run by the founders and their California-based team. The acquisition will allow Little West to leverage PlantX’s superb e-commerce platform, unique technical business expertise, and considerable marketing resources to support Little West’s premier products and accelerate the company’s growth across the U.S. and Canada. The anticipated positive impact of the transaction goes both ways. The Acquisition of Little West will provide PlantX with expertise in the cold-pressed juice segment, which is expected to further support the company’s growth in the North American market. Cold-pressed juices are gaining traction worldwide on the back of increasing health awareness of the growing middle-class consumers. Minimally processed and high-quality products such as organic and natural ingredients are especially in demand. The global market is projected to grow at a CAGR of 6.1% from 2020-2025, with North America as the largest market, followed by Europe, where premiumization is an increasing trend. Committed to eliminating the barriers to entry for consumers seeking to live a plant-based lifestyle and thrive in a longer, healthier and happier life, PlantX carefully chooses additions to its brand portfolio – and Little West appears to be no exception. Notwithstanding huge success and growth, Little West LLC prides itself on remaining true to its community roots and continues to source all fresh produce such as fruits and vegetables from local family farms. The company is devoted to sharing value it derives from its rapid success with the community by donating a part of all profits to Big Green Learning Gardens. It is also committed to giving back to nature by planting one tree for every online order to offset carbon emissions. “It is truly exciting to finalize our acquisition and partnership with Little West,” said Sean Dollinger, PlantX Founder. “We’ve already seen a lot of interest in the Little West cold-pressed juices since we announced our intention to acquire this amazing company, and we are very much looking forward to working together with Little West team and capitalize on our mutual strengths to enhance the company’s growth moving forward.” As the one-stop-shop for everything plant-based, PlantX is poised to leverage its expertise and other valuable resources to capitalize on the combined strengths of the two businesses to secure rapid growth across the North American market. Premium quality cold-pressed juices complement the existing product portfolio that includes more than 10,000 plant-based products offered to customers across North America. The company appears poised to develop further its brand portfolio with plans underway to expand its product lines to include cosmetics, clothing, and its own water brand. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. To visit the company’s YouTube channel, click here. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• In January, Splash Beverage Group acquired Copa Di Vino, leading producer of “wine by the glass” in U.S., immediately creating relationship with Copa Di Vino distributor Pepin Distributing
• Pepin has built distribution empire in Tampa Bay region to include distribution of 168+ premium brands with annual sales of over 10 million cases, 150,000 barrels of national and craft beers, growing wine and spirits portfolio
• Pepin has now added Splash’s SALT naturally flavored 100% Blanco agave tequila line to its product offerings, which will offer considerable exposure to Tampa’s large millennial population

Now that the world has reached a generational inflection point where nearly 80 million millennials outnumber other generations, getting in front of this group’s trends and all their spending power can have a substantive effect on a company’s top and bottom lines. For a spirits company, that’s where having an existing distribution network in a prime millennial region can lead to horizontal growth and a meaningful increase in sales. This month, that’s the exact scenario that played out for Splash Beverage Group (OTCQB: SBEV), as an acquisition was a gateway to get another product into the Tampa, Florida markets. Splash is a portfolio company offering several types of alcoholic and non-alcoholic beverages, ranging from TapouT performance drink to a unique line of naturally flavored tequila. In January, the Fort Lauderdale-based company acquired Copa Di Vino, the leading producer of premium “wine by the glass” in the U.S. With the acquisition came a relationship with Pepin Distributing, a 54-year-old wine and spirits distributor that purveys Copa Di Vino in the greater Tampa Bay region. Since its founding in 1967, Pepin Distributing has seen considerable growth, now employing about 280 people and distributing over 168 premier brands with annual sales that exceed 10 million cases and 150,000 half barrels of Anheuser Busch and other craft beers as well as a growing wine and spirits portfolio. Tampa is a hotbed for millennials, people aged 24-39 by common definitions, as the median age of a Tampa resident is 34.7 years (https://ibn.fm/eNbWN). The ethos of millennials is rooted in experience and variety, an identity lending to the increased popularity of tequila. As noted by ResearchAndMarkets.com (https://ibn.fm/cde6J), “growing demand from millennials is one of the prime reasons driving the tequila market in U.S. growth during the next few years.” Under the new ownership of Splash, it didn’t take long for the relationship with Pepin to expand from only Copa Di Vino to now include Splash’s SALT naturally flavored 100% Blanco agave tequila line. SALT comes in three flavors: berry, citrus and salted chocolate. SALT tequila is grown, distilled, and bottled in the Jalisco region of west-central Mexico. The region is famous for its tequila and is home to George Clooney’s Casamigos Blue Webber agave tequila that was bought by liquor giant Diageo (NYSE: DEO) in 2017 for up to $1 billion. The expanded relationship with Pepin is representative of the model of Splash to make synergistic acquisitions on any number of levels, be it manufacturing, marketing or distribution. “The acquisition of Copa di Vino was a boon for us in a number of ways, and this further proves out our investment model, which is conducive to exponential growth as we continue to expand our sales force and selective acquisitions and/or brand developments,” said Splash President and CMO Bill Meissner. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• A partnership with Medical Kiwi LTD makes it possible for RYAH to enter the New Zealand Market
• Medical Kiwi was the first South Island-based company to be granted a Medicinal Cannabis license from the Ministry of Health to cultivate
• The potential market for medical cannabis in New Zealand is at NZ$1.5 billion

RYAH Group (CSE: RYAH), a health care analytics and technology company, has entered the New Zealand market through a definitive wholesale supply and distribution agreement with Medical Kiwi LTD (https://ibn.fm/jN4T7). This agreement enables RYAH’s suite of IoT devices and cloud-based data analytics to be used in pre-clinical and clinical trial settings and medical patient care alongside Medical Kiwi’s medical cannabis formulations.

“Our new partnership with Medical Kiwi Ltd in New Zealand further expands our global clinical and distribution network for plant-based medicine and digital patient care,” said Gregory Wagner, CEO of RYAH Group Inc. and of RYAH Medtech, Inc.

Medical Kiwi is a leader in research and development, manufacturing, cultivation and distribution of medical cannabis and medical devices in New Zealand. The Company has built a strong health-based, scientific and business savvy team. It offers assurance from seed to sale and has built a reputation on innovation, excellence, quality, transparency and service. It was the first South Island-based Company to be granted a Medicinal Cannabis license from the Ministry of Health to cultivate.

It is difficult for importers of cannabis to enter the New Zealand market, and many who were once there are pulling out, unable to meet stiff new government standards (https://ibn.fm/J0M4I). Medical Kiwi’s medical cannabis formulations are cultivated, produced, and sold domestically. The analytics that RYAH’s IoT and cloud-based data analytics will help provide the necessary information the country desires in its journey to find safer, more effective medicinal products and better understand the medicinal effects.

RYAH is not the cannabis supplier but instead creates partnerships that enable doctors and patients to personalize plant-based treatments to predict treatment outcomes better. The artificial intelligence platform aggregates and correlates HIPAA-compliant patient data throughout the patient session and formulation lifecycle.

The Ministry of Health estimates that over 250,000 casual cannabis users use it for medicinal purposes, with a potential market estimated at NZ$1.5 billion (https://ibn.fm/7cttP).

“Our new relationship with Medical Kiwi presents an opportunity for both parties to drive innovation and to deliver cutting edge plant-based medical solutions in New Zealand,” stated Wagner.

In addition to the partnership, RYAH and Medical Kiwi are looking to explore the medical device registration of RYAH’s Smart-Inhaler, the first of its kind in New Zealand.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors
• Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems
• Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies
• Past experience includes role as founding CEO of OneCity Health Services, subsidiary of NYC Health + Hospitals

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently appointed strategic advisor and venture investor Dr. Christina Jenkins to its board of directors.

Dr. Jenkins synergizes capital markets expertise with healthcare industry experience through roles that span clinical medicine, venture capital, healthcare systems and health plans. Her unique set of skills, bolstered by her multivariate perspective and extensive experience, have enabled her to create growth-optimizing strategies for healthcare providers while improving health outcomes for patients.

“We are very fortunate to have Dr. Jenkins join our Board of Directors,” said POAI Chief Executive Officer J. Melville Engle. “As a medical doctor she brings additional insight and perspectives to our team. She has participated and led companies to success in health services and will have an immediate impact at Predictive Oncology and will strengthen our strategic positioning in the market.”

Dr. Jenkins brings extensive experience to POAI through multiple leadership roles across the healthcare space. She is a Board Director for Independence Health Group—the parent organization of Independence Blue Cross and AmeriHealth Caritas—in addition to being a Board Observer for Madorra Inc., a wellness company focused on women’s gynecological health. As a Venture Partner at Phoenix Venture Partners, Dr. Jenkins co-leads the firm’s seed-stage investment strategy in the healthcare/life sciences vertical with a focus on hardware-enabled platform companies that provide innovative ways to diagnose, monitor, and treat health conditions.

Dr. Jenkins’ prior experience includes work as the founding CEO of OneCity Health Services, a subsidiary of NYC Health + Hospitals, where she led a team of 130 people in a successful $1.2B effort to design and implement technology-enabled care models and accelerate value-based payment readiness that reduced financial risk for over one million people. In addition to being an advisory board member of multiple value-generating healthcare companies, Dr. Jenkins also leads investment strategies for Portfolia’s FemTech and Active Aging and Longevity funds.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• In 2020, more than 2 billion people purchased goods or services online; e-retail sales surpassed $4.2 trillion worldwide
• New online portal features GPFT’s exclusive line of THC-free, hemp-derived CBD products
• New website allows approved affiliates to sign up to market Hourglass products through their own Grapefruit-approved channels and platforms

According to a recent report from Statista, the retail industry has undergone a transformation, with e-commerce becoming indispensable to a company’s survival (https://ibn.fm/qsJ1U). In that light, the timing appears to be ideal as Grapefruit USA (OTCQB: GPFT) launches its worldwide e-commerce website, www.HourglassOnlineStore.com. The online portal features the company’s exclusive line of THC-free, hemp-derived CBD products powered by its disruptive, patented Hourglass(TM) time-release delivery cream. “Over the last few years, e-commerce has become an indispensable part of the global retail framework,” the Statista report states. “Like many other industries, the retail landscape has undergone a substantial transformation following the advent of the internet, and thanks to the ongoing digitalization of modern life, consumers from virtually every country now profit from the perks of online transactions. As internet access and adoption are rapidly increasing worldwide, the number of digital buyers keeps climbing every year. In 2020, over two billion people purchased goods or services online, and during the same year, e-retail sales surpassed 4.2 trillion U.S. dollars worldwide.” With the launch of its “one-stop shop,” Grapefruit joins the online space, ensuring that people around the world have access to its hallmark THC-free, hemp-derived, Hourglass-powered CBD topical cream; approved affiliate resellers and the company’s online site are the only places where these Grapefruit-manufactured breakthrough Hourglass products are available. “Grapefruit’s new, easy-to-navigate website will allow approved affiliates to sign up to market and sell our THC-free, hemp-derived CBD Hourglass products through their own Grapefruit-approved channels and platforms, which will allow Grapefruit to rapidly increase the availability of our CBD product lines and enhance Hourglass brand awareness,” said Grapefruit CEO Bradley Yourist. “The public will only be able to buy the vastly superior Hourglass-powered, THC-free, hemp-derived Grapefruit CBD products from Grapefruit and/or its authorized agents and affiliate resellers. Only Grapefruit products can provide the significantly superior added bioavailability and time-release properties of the patented Hourglass delivery cream. By analogy, it’s as if Grapefruit was the only company on earth with the right to sell solar panels or electric cars.” Grapefruit has built a stellar reputation for offering only high-quality, tested and reliable products, and has become recognized for its novel delivery system, which differentiates GPFT’s Hourglass products from others in the industry. The delivery system uses patented microsized particles to slowly deliver a wide range of cannabinoids through skin topical administration, solving an ongoing barrier of absorbability. In addition to its highly effective delivery system, Grapefruit offers products that are thoroughly tested and that include a QR-coded Certificate of Analysis. This certificate provides consumers with a complete list of third-party verified ingredients, certifying each product’s cannabinoid content, purity and safety. Looking forward, Grapefruit anticipates its new e-commerce website will be home to its growing portfolio of THC-free, made-in-the-U.S., hemp-derived CBD products; the company also plans to make available on the website all future hemp, CBD-based products featuring its patented bioavailability-increasing, time-release Hourglass topical cream technology. GPFT’s direct-to-consumer e-commerce store was announced earlier this month and went live on time and under budget, Yourist said. “Grapefruit’s entire team is honored to offer both U.S. and international customers a convenient, one-stop shop to purchase our THC-free, hemp-derived CBD Hourglass time-release delivery cream-powered products.” To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• BRSF featured in industry publication as a company that transforms EEG testing in children, cutting procedure time from 30 to as little as 5 minutes.
• The need for brain diagnostics in children is on the rise, but supply and availability of EEG testing to pediatric physicians remains limited.
• BRSF has stepped in to fill the gap in unmet patients’ needs; positioning itself as a leading innovator in this field.

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, was featured in Med-Tech News, a publication covering medical devices medical manufacturing, as a Company revolutionizing the space of pediatric brain diagnostics (https://ibn.fm/Aslgm). The feature piece authored by Irina Nazarova, marketing director of Brain Scientific, brings to attention the importance of having a new generation of devices for neurological diagnostics in children and why Brain Scientific’s solution is responding to this growing but still largely unmet patient need.

Often left under the radar of technology providers working in neurological diagnostics, the pediatric market also has a need for EEG devices because children can suffer from a number of neurological disorders, including seizures, sleep issues, brain infections and epilepsy. For example, epilepsy as one of the most common neurological disorders in children could lead to dangerous seizures if left undetected. Still, this list of possible pediatric applications of brain diagnostic devices is not exhaustive — it is constantly expanding with new conditions where the novel technology can make a difference for children’s health. For example, EEG testing could also be used for diagnosing ADHD, another growing market need as the article cites Child and Adolescent Psychiatry which reports that children with the disorder make up 42% of all children in the country. It could also be crucial for diagnosing autism, another prevalent condition challenging to diagnose, especially in younger pediatric patients.

Still, despite the apparent unmet need in patient care, the supply and availability of EEG testing to pediatric physicians are limited. That was before Brain Scientific stepped up to the challenge. The article describes how the Company responded with agility to feel the gap and establish a new innovative norm for pediatric clinicians.

After showcasing adult-sized NeuroCap at several medical technology conferences, Brain Scientific was approached by many attendees inquiring if the Company has a pediatric version already available or at least in development. Committed to unveiling emerging market needs and quick to respond to them, Brain Scientific started working to respond to this challenge right away. After plenty of consultations between the Company’s in-house team of specialists and the manufacturers and the medical testers to secure high-quality products, the NeuroCap for children was born — an easy-to-use disposable headset overcoming the infection risk and inconvenience burden of traditional EEG pediatric products.

Nazarova continues explaining that the pediatric version of NeuroCap comes with all the benefits of the adult version. Unlike most EEGs, which require a special technician to conduct the testing with a single machine, one patient at a time, pediatric NeuroCap is a pre-gelled hospital-grade children-size EEG headset that any member of clinical staff can apply. Like the adult edition, the pediatric NeuroCap is quick, disposable, sanitary and comfortable, transforming once tedious process that could take up to 30 minutes per child into a painless and simple routine for medical staff. Illustrating how the pediatric NeuroCap is a game-changer for EEG testing in children, the article reports that this novel device can conduct testing in as little as five minutes, delivering prompt test results. This makes it an excellent fit for pediatric patients in emergency rooms, ICUs, and clinics.

Despite the pandemic-related supply chain challenges, Nazarova concludes that Brain Scientific continues to be committed to help better equip healthcare facilities across the country. NeuroCap for children will join the Company’s proprietary lineup of diagnostic devices to bring affordable, easy-to-use brain diagnostics solutions for children.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• China’s cloud market is experiencing tremendous growth on the back of companies shifting to and investing in cloud-based infrastructure
• These companies are looking for reduced costs and increased revenue, as well as improved customer service and satisfaction
• Infobird’s next-generation customer engagement software offers many benefits, including increased customer interaction efficiency at a reduced cost

A Forbes article on how artificial intelligence (“AI”) will impact the future of work and life observes that AI is becoming standard in all sectors. 90% of leading companies have invested in AI technologies, half of which have already reported greater productivity due to their investment (https://ibn.fm/cvnXf).

Notably, AI applications and benefits are across the board, as Infobird (NASDAQ: IFBD), a leading Software-as-a-Service (SaaS) company in China, observed in a 2020 article published on its website (https://ibn.fm/1pJYO). Infobird, which provides AI-enabled end-to-end consumer engagement solutions in the Chinese market, noted that by 2025, 95% of customer interactions would be driven by AI, from online Q&As to telephone services. So advanced will the AI tools be, the article says, that users will be unable to distinguish between a robot and a real person.

But getting to this point is a gradual process that has already begun and whose cradle, particularly within the customer-engagement segment in China, can be traced to the growth of the cloud market in the country. Here, cloud infrastructure spending grew from about $107 billion in 2019 to $142 billion in 2020 (https://ibn.fm/u5XPX), marking a near 33% year-over-year increase.

Driven by the increased acceptance of cloud and SaaS solutions and the long-term structural trends in the digitization of China’s economy, the shift to cloud-based infrastructure by companies has indeed gained traction. It has even triggered a domino effect that has seen even more companies adopt these solutions as they look to cut costs and increase revenue while still offering improved customer service and satisfaction.

Moreover, it has fused SaaS and customer engagement, leading to the emergence of proactive AI-powered SaaS solutions, i.e., the next generation of SaaS, to replace traditional efforts. Infobird is at the vanguard of this transformation (https://ibn.fm/rIxBP).

IFBD is the only SaaS company in China that owns and deploys cloud-native architecture in customer engagement that can harness the full power offered by cloud computing, including the ability to scale up capabilities flexibly. Furthermore, its cloud-based approach to customer engagement means that its platform can support potentially unlimited concurrence of agents with high failure tolerance.

Having already embraced AI, as detailed in its 2020 article, Infobird has self-developed and patented AI technologies, such as its innovative no-code development platform and its natural language processing (“NLP”) tool. These products have seen it offer customer engagement services, call center expertise and customer relationship management (“CRM”) to some of the largest enterprises in China, including one of the largest commercial banks in the country – as well as a well-known e-commerce giant, qualifying it as one of only a handful of SaaS companies to accomplish this.

The reliance on AI, which is attributed to the company’s focus on innovation, has differentiated IFBD’s customer engagement solutions from the traditional CRM tools and products from companies like Zendesk Inc. (NYSE: ZEN).

While the traditional CRM systems only passively track, monitor and analyze sales activities, Infobird’s software combines AI-enabled customer engagement and AI-powered sales force management, resulting in a more robust and intuitive platform that can be described as the “next-generation CRM.” It is also more proactive and uses a wide gamut of applications, such as AI chatbots, omnichannel communication tools and intelligent quality inspection, to continuously engage customers.

With this approach, Infobird aims to help its clients grow their interaction efficiency with their end customers at a low cost. It is also keen on capturing market share as it transitions to standardized module SaaS (https://ibn.fm/HL3Ni).

For more information, visit the company’s website at www.Infobird.com/en/index.html

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health
• The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe
• In an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking to expand distribution to various markets, including the Middle East

In an interview on Proactive on March 22, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO and Director Hugh Rogers explained the implications of the CE-IVD approval (European certification) the company’s 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”) had just received. One notable remark was that this approval would facilitate the sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East, and North America (https://ibn.fm/RJWe5).

XPhyto, a life sciences technology accelerator, recently announced the delivery of 2,000 units of Covid-ID Lab to an established medical distributor in Israel, signaling its entry into the Middle East, subject to commercial regulatory approval and subsequent potential product distribution (https://ibn.fm/2gS4J).

These units will be used for clinical evaluation based on the European CE-IVD approval, one of several international medical device certifications recognized by the Israeli government. The evaluation, expected to be completed within 90 days, will be conducted by the Medical Device Division of the Israeli Ministry of Health (“AMAR”).

“We are excited by the opportunity to expand potential distribution beyond Germany,” said Rogers. “We are building strong partnerships around the world, and Israel is a leading nation for COVID-19 management and research.”

One such partnership is with the Israeli distributor, which markets and distributes a range of medical products, including diagnostics, in Israel and surrounding countries. It has an extensive portfolio of customers in both the private and public sectors, such as the government, pharmacies, hospitals, and health care providers.

XPhyto is banking on the fact that rapid and accurate testing will undoubtedly continue being a vital tool for monitoring and managing the pandemic for many years to come. This is despite the successful rollout in various countries, including Israel. In fact, the Middle Eastern country had already vaccinated about 58.5% of its population as of April 13 (https://ibn.fm/m4auk).

Vaccines are not 100% effective in preventing COVID-19 infection. As such, vaccinated people should still undertake regular testing to lower the risk of spreading the disease, especially with the emergence of new, more lethal variants. Experts consider testing an indicator of where the disease is localized and to which areas it is spreading (https://ibn.fm/hYDWd). During the Proactive interview, Rogers had alluded to these facts.

“As vaccines roll out, it’s going to be inconsistent across jurisdictions for various logistical and economic reasons. So, you can expect testing at any border control (point), (before) international travel and even (when) monitoring the efficacy of the vaccine. You are looking at significant testing for several years,” Rogers noted.

This outlook has enabled XPhyto to expand distribution beyond Germany, where it has already signed a distribution agreement (https://ibn.fm/ZfJZA), potentially to other areas of the world. Seeing that the company is on track to actualize its plan to enter the Middle East, entry into the North American market may well be on the horizon.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Communications and insurtech services company FingerMotion is rolling out its Sapientus platform for analyzing big data input
• The company is in a unique position because it is the only officially licensee for mining and analyzing data from Chinese telecommunications giants China Unicom’s and China Mobile’s customers
• FingerMotion’s access to the 1.1 billion consumers’ data led to a partnership with insurance giant Pacific Life in January as Pacific Life looks for ways to grow within China’s insurance industry
• The deal’s anticipated ability to establish a landmark credit rating system among China’s billions of consumers at a time when no developed credit reporting similar to the U.S. system exists is expected to revolutionize the industry there

As China becomes the world’s most actively percolating hotbed for big data analytics and their real-time application, opportunities to invest in the country’s industries are expected to see growth at a CAGR of 30 percent over the next five years, according to a report by Mordor Intelligence (https://ibn.fm/RE8av).

Evolving communications and insurance tech company FingerMotion (OTCQX: FNGR) has established its name through its telecommunication products and services and its SMS and MMS services divisions in recent years, but the formal launch of its rich communication services (“RCS”) and big-data insights this year are expected to elevate it to as-yet-unseen revenue levels thanks to its exclusive positioning in regard to analyzing big data in China.

FingerMotion is the only company with a license to legally mine and analyze the mobile data of telecommunications giants China Unicom and China Mobile customers, which represents over 1.1 billion phones. The data derived directly from customers’ mobile products means FingerMotion doesn’t have to maintain its own database, and the mobile products are likely to provide the most accurate assessment of customer behavior.

FingerMotion’s access to Chinese consumers’ data led to the announcement of a profitable partnership with Pacific Life’s reinsurance division in January (https://ibn.fm/E0HCz). Pacific Life is one of the world’s top five Insurance companies with $1.1 trillion in life insurance policies, $171 billion in assets, and a 150-year-plus history (https://ibn.fm/T0Fqj).

We are very excited about this joint undertaking as we believe this collaboration will create a transformative environment that could leave evolutionary imprints in the insurance industry with respect to risk assessments, customer insights, and more importantly innovative solutions that will enhance the overall customer experience,” FingerMotion CEO Martin Shen said at the time (https://ibn.fm/FDs1B).

The deal effectively establishes FingerMotion as Pacific Life Re-insurance’s data provider as Pacific Life pursues solutions for growing within the Chinese insurance industry. Insurance is mandatory in China, and the innovation of FingerMotion’s Sapientus platform is that it overlays consumer data with AI-driven behavioral analytics to help provide predictive measures about the consumers’ habits.

Since China doesn’t maintain a developed credit rating system such as that employed in the United States by insurance agencies to assess their risks in policy undertakings (https://ibn.fm/GxiWh), the big data analysis is being tapped as a proxy measure of that fundamental concern.

A credit score can be built on the consumers’ pseudo-self-reporting about habits such as whether they frequent fast food places, drive over the speed limit, text while driving, smoke cigarettes, etc. Consumers can reap rate rewards for beneficial behaviors at the outset based on the predictive models.

FingerMotion anticipates that its year-end financial report will show revenues topping $16 million for the fiscal year that ended Feb. 28, when it issues the report sometime during the next few weeks (https://ibn.fm/Asj5R).

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Healthy Extracts Inc. through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”) is focused on building a stronghold in the nutraceuticals market
• BergaMet NA is the only company authorized to manufacture, distribute, and sell Citrus Bergamot SuperFruit(TM) in North America, a supplement enriched with the world’s best quality polyphenols and flavonoids
• BergaMet North America’s HERHEART(TM) is a natural supplement, scientifically formulated to support woman’s cardiovascular health, as well as managing perimenopausal symptoms

Healthy Extracts (OCTQB: HYEX) through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”) is focused on the proprietary research, development, and sale of natural plant-based formulations offering supplements, beneficial for cardiovascular and neuro health. These two-million-dollar industries catering to the high-margin and high-growth categories reflect the company’s commitment to strengthening its position in the multibillion-dollar nutraceuticals market.

Acquired by Healthy Extracts in 2019, BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit(TM) called “Bergamot”, the only heart health supplement backed by 17 clinical studies. The Bergamot supplement is enriched with the world’s best quality polyphenols and flavonoids, proving a boon to thousands of people who suffer from cardiovascular diseases. BergaMet NA is the only company authorized to manufacture, distribute, and sell these products in the United States, Canada, and Mexico.

Enriched with antioxidant polyphenols, BergaMet is a Mediterranean fruit whose immense health properties have been supported by Dr. Joel Kahn, M.D., an eminent, triple board-certified cardiology specialist, who recently joined the company’s medical board. Dr. Kahn advocates the benefits of using BergametNA Citrus Bergamot SuperFruit for heart health namely positive arterial age reversal and arterial flexibility. He has tested the formulation on several patients and approved the product’s cardiovascular health benefits along with no known side effects (https://ibn.fm/ciDXF).

Research and clinical studies show positive results for two leading products of the company, BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. Clinical studies show positive results in brain activation, sports vision, cognitive function, clarity, energy, and ketone benefits (https://ibn.fm/mhX7W).

HERHEART(TM) is a natural supplement, being touted to become the company’s top-selling products, under the leadership of the world-renowned health expert Dr. Nesochi Okeke-Igbokwe MD., M.S, who recently joined the company’s Medical Advisory Board. The formulation is scientifically formulated to support a woman’s cardiovascular health, as well as managing perimenopausal symptoms (https://ibn.fm/M10yz).

For more information, visit the company’s website at www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending.

For more information visit: www.healthyextractsinc.com, www.bergametna.com or www.fuel4thought.com

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Healthy Extracts Inc.
Las Vegas, Nevada
www.healthyextractsinc.com
info@healthyextractsinc.com
720-463-1004

Corporate Communications:
InvestorBrandNetwork (“IBN”)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com